ReviewMolecular medicine reports2026
Biomarkers of radioresistance in lung cancer: Current insights and future directions (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy (RT) remains a cornerstone of lung cancer (LC) management, serving as either a definitive treatment or an adjuvant modality following surgical resection. Nevertheless, a major challenge for radiation oncologists is the emergence of radioresistance, whether intrinsic or acquired, which contributes to therapeutic failure, tumor recurrence, metastasis and ultimately to increased patient mortality. Radioresistance is a multifactorial process driven by genetic and epigenetic alterations that dysregulate key signal transduction pathways, enabling cancer cells to survive and adapt under radiotherapeutic stress. A deeper understanding of the molecular mechanisms underlying radioresistance is therefore essential to identify robust biomarkers for patient stratification, prognostication and therapeutic targeting. Such insights could enable individualized treatment strategies within the framework of precision oncology and inform the development of novel radiosensitization approaches to overcome resistance in LC. The present review synthesized current evidence on molecular biomarkers associated with RT resistance in LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.